Table 2.
Crude event rates for CVD death, total mortality, CVD Composite Events, and ESRD for the AASK
| Patient Subgroup | All ESRD |
CVD Composite Event |
All Death (Censoring Follow-up at ESRD) |
CVD Death |
||||
|---|---|---|---|---|---|---|---|---|
| Total N (No. of Events; %) | Rate/100 patient-years | Total N (No. of Events; %) | Rate/100 patient-years | Total N (No. of Events; %) | Rate/100 patient-years | Total N (No. of Events; %) | Rate/100 patient-years | |
| All patients | 1094 (318; 29) | 3.9 | 1094 (225; 21) | 3.2 | 1094 (177; 16) | 2.2 | 1094 (59; 5) | 0.8 |
| Age (years) | ||||||||
| ≤55 | 524 (207; 40) | 5.4 | 524 (95; 18) | 2.9 | 524 (52; 10) | 1.4 | 524 (22; 4) | 0.6 |
| >55 | 570 (111; 19) | 2.6 | 570 (130; 23) | 3.5 | 570 (125; 22) | 2.9 | 570 (37; 6) | 0.9 |
| Baseline UP/Cr | ||||||||
| ≤0.22 | 733 (109; 15) | 1.8 | 733 (155; 21) | 3.0 | 733 (123; 17) | 2.0 | 733 (43; 6) | 0.8 |
| >0.22 | 357 (208; 58) | 10.5 | 357 (69; 19) | 4.0 | 357 (53; 15) | 2.7 | 357 (16; 4) | 0.9 |
| Education | ||||||||
| high school or higher | 648 (209; 32) | 4.3 | 648 (115; 18) | 2.7 | 648 (88; 14) | 1.8 | 648 (30; 5) | 0.7 |
| lower than high school | 444 (109; 25) | 3.3 | 444 (110; 25) | 4.0 | 444 (88; 20) | 2.7 | 444 (29; 7) | 1.0 |
| Gender | ||||||||
| female | 425 (135; 32) | 4.2 | 425 (82; 19) | 3.0 | 425 (52; 12) | 1.6 | 425 (20; 5) | 0.7 |
| male | 669 (183; 27) | 3.7 | 669 (143; 21) | 3.4 | 669 (125; 19) | 2.5 | 669 (39; 6) | 0.8 |
| Income | ||||||||
| <$15,000 | 521 (152; 29) | 4.0 | 521 (118; 23) | 3.7 | 521 (87; 17) | 2.3 | 521 (29; 6) | 0.8 |
| ≥$15,000 | 370 (107; 29) | 3.8 | 370 (68; 18) | 2.7 | 370 (56; 15) | 2.0 | 370 (17; 5) | 0.6 |
| declined to answer | 203 (59; 29) | 4.0 | 203 (39; 19) | 3.0 | 203 (34; 17) | 2.3 | 203 (13; 6) | 0.9 |
| Mean baseline GFR | ||||||||
| >40 | 718 (106; 15) | 1.7 | 718 (160; 22) | 3.1 | 718 (112; 16) | 1.8 | 718 (41; 6) | 0.7 |
| ≤40 | 376 (212; 56) | 10.2 | 376 (65; 17) | 3.5 | 376 (65; 17) | 3.1 | 376 (18; 5) | 0.9 |
| Preexisting CVD | ||||||||
| yes | 564 (147; 26) | 3.5 | 564 (132; 23) | 3.7 | 564 (105; 19) | 2.5 | 564 (41; 7) | 1.1 |
| no | 530 (171; 32) | 4.2 | 530 (93; 18) | 2.7 | 530 (72; 14) | 1.8 | 530 (18; 3) | 0.5 |
Shown are unadjusted incidence rates. Follow-up for CVD events and mortality was terminated at occurrence of ESRD. The follow-up time for ESRD and mortality outcomes included the trial, cohort, and transition periods. The follow-up time for CVD events and CVD deaths included the trial and cohort periods. Similar incidence rates were obtained for each outcome in a sensitivity analysis in which the transition period between the trial and cohort periods was excluded for all events.